StoxSun Pharmaceutical Industries vs Apollo Hospitals Enterprise: share price & financials comparison
NSE: SUNPHARMA vs APOLLOHOSP · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Sun Pharmaceutical Industries vs Apollo Hospitals Enterprise at a glance
Sun Pharmaceutical Industries (SUNPHARMA) has a market capitalisation of ₹4,46,270 Cr, against ₹1,21,453 Cr for Apollo Hospitals Enterprise (APOLLOHOSP). Over the past year Sun Pharmaceutical Industries has returned +8.4%, compared with +7.5% for Apollo Hospitals Enterprise. On valuation, Sun Pharmaceutical Industries trades at a lower P/E of 40.7 versus 54.2. Apollo Hospitals Enterprise earns a higher return on equity (21.1% vs 12.3%). Sun Pharmaceutical Industries comes out ahead on size, valuation, profitability and financial health. Apollo Hospitals Enterprise comes out ahead on growth, momentum and technicals. Across the scored metrics below, Sun Pharmaceutical Industries leads on 9 and Apollo Hospitals Enterprise on 9. On StoxGud's 10-point checklist, Sun Pharmaceutical Industries scores 8/10 and Apollo Hospitals Enterprise scores 8/10.
| Metric | Sun Pharmaceutical Industries | Apollo Hospitals Enterprise |
|---|---|---|
| Size | ||
| Market cap | ₹4,46,270 Cr | ₹1,21,453 Cr |
| Revenue (latest FY) | ₹58,462 Cr | ₹25,228 Cr |
| Net profit (latest FY) | ₹11,479 Cr | ₹1,942 Cr |
| Valuation | ||
| P/E | 40.7 | 54.2 |
| P/B | 5.00 | 11.45 |
| Dividend yield | 0.88% | 0.24% |
| Profitability | ||
| Return on equity | 12.3% | 21.1% |
| Net profit margin | 17.8% | 8.1% |
| Operating margin | 29.3% | 15.4% |
| Growth | ||
| Revenue growth (YoY) | +11.9% | +20.8% |
| Net profit growth (YoY) | -36.2% | +32.0% |
| Revenue CAGR (multi-year) | +11.8% | +19.0% |
| Financial health | ||
| Debt to equity | 0.03 | 0.53 |
| Momentum | ||
| 1-month return | +4.4% | +6.7% |
| 1-year return | +8.4% | +7.5% |
| 3-year CAGR | +17.4% | +17.8% |
| 5-year CAGR | +18.4% | +13.9% |
| 10-year CAGR | +11.0% | +20.8% |
| Distance from 52W high | -7.1% | -6.9% |
| Technicals | ||
| RSI (14) | 77 | 66 |
| Price vs 200-day avg | +2.7% | +3.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Sun Pharmaceutical Industries | Apollo Hospitals Enterprise |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 8/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Sun Pharmaceutical Industries or Apollo Hospitals Enterprise?
Sun Pharmaceutical Industries has a market cap of ₹4,46,270 Cr and Apollo Hospitals Enterprise has a market cap of ₹1,21,453 Cr as of 06 Nov 2026.
Which has a lower P/E, Sun Pharmaceutical Industries or Apollo Hospitals Enterprise?
Sun Pharmaceutical Industries has the lower P/E: Sun Pharmaceutical Industries trades at 40.7 and Apollo Hospitals Enterprise at 54.2.
Which gave better returns in the last year, Sun Pharmaceutical Industries or Apollo Hospitals Enterprise?
Sun Pharmaceutical Industries did better: Sun Pharmaceutical Industries returned +8.4% and Apollo Hospitals Enterprise returned +7.5% over one year.
Is Sun Pharmaceutical Industries or Apollo Hospitals Enterprise a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Sun Pharmaceutical Industries scores 8/10 and Apollo Hospitals Enterprise scores 8/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.